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REVIEW
Background: Drug reimportation is perceived as a costs-cutting strategy by Americans.
Nonetheless, issues such as drug safety and efficacy prevent legalization of the practice. With
the contradictory views from supporters and opponents, debate on drug reimportation continues
to snowball. The objective of this commentary is to discuss issues regarding drug reimportation
practices in the United States (US). It also examines policy implications and potential solutions
of the controversy.
Findings: Comparatively inexpensive drugs available across the border help Americans relieve
the burden of medication costs. Consequently, the volume of reimported drugs entering the
US has considerably increased. However, these practices are illegal and legalization of drug
reimportation is a political debate. While safety is the most important barrier for legalization,
this concern does not seem to affect growing number of Americans who are getting their
prescriptions filled from across the border. Canadians oppose legalization of reimportation in
the US as it could exacerbate the problem of medication shortage in Canada.
Summary: Currently, legalization of dug reimportation has wedged between the arguments
by different groups. Until the US government finds a solution to reduce medication costs, it
seems to be impossible to stop Americans from buying the comparatively inexpensive
medications available across the border.
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Background
The increasing expenditure on prescription medications is a big concern for consumers
in the United States (US). Due to the increasing burden of medication costs,
Americans, especially elderly and the uninsured, avoid taking medications or skip
doses. According to a study, 22% of seniors do not fill their prescriptions because
they cannot afford the cost of their medications (Safran et al 2002). The percentages
are higher (32%) for uninsured population, which account for approximately 10% to
15% of the US population (Safran et al 2002).
Consequently, a growing number of Americans choose to buy comparatively
inexpensive medications available in other countries such as Canada and Mexico.
Several internet pharmacies help consumers obtain medications from other countries
without requiring them to travel across the borders. Even though these drugs are
often manufactured in the US, the drug price control acts in countries like Canada
keep the prices of prescription medications lower than the US market prices (Wagner
and McCarthy 2004). The practice of importing back to the US prescription drugs
that were originally manufactured in the US and exported for sale in another country
is referred as ‘drug reimportation’. Estimates indicate that buying medicines from a
certified Canadian pharmacy can save Americans 20%–80% on brand name drugs
(Vivian 2003). However, economists argue that these estimates could be dubious
and are overestimated considering the complications involved in comparing
medication prices across different nations (Danzon and Kim 1998; Wagner and
McCarthy 2004).
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Many concerns restrict drug reimportation from being a
legal practice in the US. These include safety, efficacy, and
therapeutic equivalency of reimported drugs. While these
drugs are manufactured in the US, the storage and packaging
conditions in countries where drugs were exported cannot
be monitored by the US Food and Drug Administration
(FDA) (Meadows 2002). In addition, inappropriate storage
conditions while reimporting medications back to the US
may degrade the quality of drugs. The most important issue
is distinguishing between drugs that are manufactured in
the US from those which were manufactured elsewhere.
Although technically ‘reimportation’ involves importing
back drugs manufactured in the US, there are no means to
check the originality of drugs. Similarly, it is difficult to
determine whether the drugs purchased from other countries
have the same dosage form, potency, and amount of active
ingredient as the prescribed medication. The FDA contends
that legalizing reimportation would increase the entry of
counterfeit medications in the US drug supply chain
(Meadows 2002). The pharmaceutical industry criticizes the
reimportation practice due to the potential harm to the
recovery of the research and development (R&D) costs
required for new drugs (Danzon 1998; Danzon and Kim
1998). While these opponents prevent the legalization of
drug reimportation, various consumer advocacy groups
support the practice.
The legalization of drug reimportation remains a
controversial issue in the US. While important, limited work
has been done on briefing the legislative history and current
status of drug reimportation. This commentary tries to
explore the perspectives of different groups, emphasizing
the role of healthcare professionals in drug reimportation
practices. In addition, the paper also discusses policy
implications of the drug reimportation practice.
Key findings
US prescription drug expenditure and
drug reimportation
The cost of prescription drugs is the fastest growing sector
of US healthcare costs. In 1980, US prescription drug
expenditures were $12 billion, accounting for 4.9 % of total
healthcare spending. By 2003, it had escalated to $184.1
billion or 11.0% of total healthcare expenditures (CMS
2005). The increased volume of prescription medications
have also driven the overall costs of pharmaceuticals. The
increasing number of prescription uilization was responsible
for 42% of the overall increase in prescription spending from
1997–2002 (KFF 2004) (Figure 1).
On the other hand, measures such as drug price control
acts in other countries such as Canada significantly reduce
the prices of prescription as compared with the US.
 Thus in
most cases, Americans can buy the same medication at
significantly lower prices from countries like Canada and
Mexico. For instance, the antiretroviral drug ritonavir
(Norvir
®, Abbott Laboratories), which is a part of many HIV/
AIDS treatments costs as low as $700/per year in Canada
as opposed to $7800/per year in the US (Nelson 2004).
According to the Patented Medicine Review Prices Board
of Canada (PMPRB), factory drug prices in the US exceeded
seven nations including Canada and European countries in
the year 2000. Consequently, the volume of reimported drug
entering the US has significantly increased over the past
decade (Dalzell 2000)
Legislative history
Various bills allowing reimportation of drugs have been
proposed, but none of them have been implemented as
legislation yet. The practice of reimportation is illegal in
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Figure 1 Prescription drug expenditure and % of total healthcare expenditure for 1998–2013 (CMS 2005).Therapeutics and Clinical Risk Management 2007:3(1) 43
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the US (the legal exceptions are those drugs which are
manufactured in the US, and may be reimported by the
original manufacturer or if the prescription drug is required
for ‘emergency medical care’) (Creech 2001). The FDA also
allows 90-day supply of reimported drugs for personal use
(Reichertz and Friend 2000). In 2000, the Medicine Equity
and Drug Safety Act of 2000 (MEDS act) was passed to
allow pharmacists and wholesalers to reimport US
manufactured, FDA approved drugs, previously exported
to foreign countries, back into the US to sell them to
Americans at cheaper prices. However due to lack of the
congressionally required certification by the Department of
Health and Human Services (HHS), the MEDS act was
terminated at the end of December 2000 (Vogel and Joish,
2000). Before the proposal of this act, the Prescription Drug
Marketing Act of 1988 (PDMA) allowed manufacturers to
reimport drugs under FDA regulation (Creech 2001).
Several times since 2000, both the US House of
Representatives and the Senate have continuously discussed
this issue in an effort to legalize reimportation practices.
On July 25, 2003, the Pharmaceutical Market Access Act
of 2003 (H.R. 2427) passed in the House had provisions to
allow drug reimportation from 25 countries, including
Canada, Australia, Japan, South Africa, and the European
Union. A different version of this bill was passed in the
Senate in June 2003 that allowed reimportation of FDA-
approved drugs only from Canada (Moskowitz 2000).
 As a
safety measure, this legislation required that the packaging
of prescription drugs incorporate counterfeit-resistant
technology. It also entailed a certification from the Secretary
of Department of Health and Human Services that the
prescription drugs do not expose consumers to any
additional risks.
Currently the debate on drug reimportation practice
continues to snowball although its status is still illegal. The
legal status of reimportation may be misinterpreted by the
consumers due to the ambiguous nature of different
amendments and bills. A survey by IMS Health Inc in 2003
revealed that 45% of the respondents perceived
reimportation practices to be legal, and 33% were unsure
(Saatsoglou 2004). These results indicate consumers’
unawareness regarding legality of drug reimportation
practices.
Perspective of the US FDA
The arguments about safety and legitimacy of reimported
drugs restrict the legalization of the practice. The FDA has
consistently denied guaranteeing the safety, efficacy and
legitimacy of reimported prescription drugs. The FDA
claims that there are no means to detect the origin of the
drugs despite the fact they are manufactured in the US
(Meadows 2002). The FDA argues that they do not have
sufficient financial as well as technological resources to
assure the safety and authenticity of drugs coming from
across the border (Thompson 2000). Following are some
of the key findings (FDA 2003, 2004; FDA Consumer 2003;
Rudolf and Bernstein 2004) that support FDA’s positions
on drug reimportation practices:
• The FDA and the Customs and Border Protection carried
out a series of “blitz” examinations of 1982 drug
packages mailed or shipped to individual recipients from
abroad. Approximately 90% of these products were
found to be unapproved and to present potentially severe
health risks. The examined imports included drugs that
had been withdrawn from the US market as unsafe; drugs
with restricted distribution programs; drugs requiring
initial screening and periodic monitoring of patients to
ensure safe use; controlled substances such as codeine;
animal drugs sold for human use; and drugs that might
cause dangerous drug–drug interactions.
• The majority of the drugs had unknown quality and
originated from Third World countries.
• The labeling and packaging of the reimported drugs may
not be according to the FDA standards. Some
medications with labels and inserts in different languages
were found during the FDA inspection.
• In another case, FDA officials examined drugs ordered
from a supposed Canadian pharmacy. These drugs,
(including insulin) arrived in the regular mail and at room
temperature (Insulin loses effectiveness at higher
temperatures and is supposed to be shipped overnight
to ensure it remains chilled) (Vogel 2002).
•  The World Health Organization anticipated that in 2000
about 8% of bulk drugs imported to the US were
counterfeit, unapproved, or substandard.
• The FDA claims that the number of counterfeit drugs
investigated per year have increased to 20 since 2000
after averaging 5 per year in late 90s.
Drug reimportation is considered as a threat to recover
the costs required for the new drug discovery. The
pharmaceutical industry depends on patents to fund the R&D
costs for new drug products. Pharmaceutical price controls
reduces the amount of profit available for further R&D,
which in turn affects the innovation (Vogel 2002). The
average cost of bringing a new drug to market is estimated
at almost $800 million (DiMasi et al 2003). These costsTherapeutics and Clinical Risk Management 2007:3(1) 44
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could be recovered through branded medications since the
prices of generic and over-the counter medications need to
be set according the market competition. To recover the costs
of innovation and to gain profit, companies set prices
according to the different levels of demand and price
sensitivity across the different markets (Danzon 1998;
Danzon and Kim 1998).
Perspective of US consumers on drug
reimportation
While reimportation remains a controversial issue, these
concerns do not seem to affect growing number of
Americans who chose to buy their prescription medications
from across the border. Currently the estimates available
indicate that 1 to 10 million of Americans purchase drugs
from Canada alone, and spend more than $1.1 billion on
these prescription drugs in 2003 (Finkelstein 2003). Survey
results from various organizations reveal some interesting
results. A national survey by researchers at Stony Brook
University revealed that around 58% of the consumers
perceive Canadian drugs to be safe or somewhat safe and
68% think that the practice should be legalized (SBU 2003).
According to a survey by Kaiser Family Foundation (KFF),
63% consumers support drug reimportation and believe that
the federal government should make it easier for Americans
to get access to Canadian drugs (KFF 2003).
Canadian perspective on US drug
reimportation
It is important to consider the drug reimportation issue from
the Canadian perspective as well. A few US drug companies
have already cut off drug supplies to the Canadian
pharmacies that sell prescription drugs to US consumers
(Elliott 2003). This has led to serious drug shortages at these
pharmacies. Also, Canada’s drug supply is very limited and
cannot service the need of the whole American population
(Graham 2003). Considering the lucrative nature of the drug
reimportation business, there is a high possibility that in
fulfilling the increased demand of US consumers, Canadian
pharmacists might order drugs from other countries such as
India, Thailand, and Africa where the rate of drug
counterfeiting could be higher. Nonetheless, various
Canadian pharmacies available on the internet could be
bogus and ordering medications from such online
pharmacies could be dangerous (Mulligan 2003).
Is reimportation really a cost beneficial
strategy?
While international price comparisons of medications show
the comparatively higher prices in US, economists argue
that international comparisons must be viewed with
skepticism (Danzon 1998). Medication prices in other
countries generally reflect the lower incomes in some states
and the highly politicized nature of most foreign healthcare
systems. Exchange rate variations also play a role in setting
medication prices. The US has a relatively strong dollar in
comparison with other countries, which could have made
medications in some other countries seem particularly
inexpensive. Research by Danzon and Kim (1998) studied
the issues of patent protection, price controls, and continuing
availability of prescription drugs without prescriptions. After
adjusting for such factors as well as the role of generic
equivalents, volume discounts, and frequency of use, they
found that the average US consumer would have paid 3%
more in Canada, 27% more in Germany, 30% less in France,
9% less in Italy, 8% less in Japan, 44% more in Switzerland,
9% more in Sweden, and 24% less in the UK.
Practices such as reference pricing and parallel trade,
which are allowed in European Union (EU), may erode
above-normal profits of the pharmaceutical industry if
allowed in the US. While the concept of parallel trade is
attractive, economic analyses showed that differential
pricing is in fact beneficial for recovering costs of R&D of
new drugs (Vogel and Joish 2001).
The medication costs issues in the US are mainly
associated with brand name drugs. According to a new study
by the FDA, Americans who buy drugs in Canada in hopes
of saving money could pay significantly more for certain
prescription drugs than if they had purchased generic
versions of these drugs in the US. This study found that out
of seven top-selling prescription drugs for chronic disease,
six generic US versions cost significantly less than their
Canadian equivalents (FDA 2003).
 A Canadian study of 27
top-selling generic prescription drugs concluded that three-
fourths of those drugs cost less in the US, and Canadians
could save millions by access to the US versions (D’Angelo
2002). These findings are asserted by another study, which
found that US, on average, had higher prices for new
originator products, but had the lowest generic prices
compared with countries including Canada, Chile, France,
Germany, Italy, Japan, Mexico, and the UK. The US also
had the lowest over-the-counter drug prices (Danzon and
Kim 1998).Therapeutics and Clinical Risk Management 2007:3(1) 45
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Costs involved in legalization of drug reimportation
should not be neglected as well. The major emphasis for
legalizing the practice of reimportation in the US has been
the cost savings it offers. However, based on the estimates
by Congressional Budget Office (CBO), enactment of the
H.R. 2427 bill that allows reimporting drugs into the US
would reduce total prescription drug spending by only about
1% or US$40 billion in the next decade (CBO 2003). Few
economists and researchers have concurred that drug
reimportation might not be a panacea for the soaring drug
costs (Thompson 2004). To ensure the safety and
authenticity of reimported/imported drugs, researchers have
proposed using anti-counterfeiting technology for
medication packages to avoid the entry of spurious
prescription drugs in the US. According to the FDA
estimates, this anti-counterfeiting technology would cost
approximately $2 billion.
Policy implications and suggested
potential solutions
Legalizing the reimportation practices might not solve the
problem of growing prescription medication costs. Drug
reimportation certainly involves potential threat of
counterfeit drugs, which could result in additional costs to
the healthcare system. The problem of high drug costs should
be solved using the combination of most safe and appropriate
treatment strategies wherever possible. One such strategy
may be to promote use of FDA-approved generic drugs.
Policymakers should promote policies allowing easy market
entry of generic drugs and increasing awareness of
Americans regarding costs-savings due to generic drug use.
The Medicare Part D, an enhancement of the Medicare
Prescription Drug, Improvement and Modernization Act of
2003, will be implemented in January 2006. This outpatient
prescription drug benefit plan has a potential to transform
American healthcare delivery by significantly reducing the
costs of prescription drugs along with increasing access to
medicines. A transitional drug discount card program that
has been ongoing since mid-2004 may be useful for elderly
consumers to manage their prescription drug expenditures.
The major challenge for the US policymakers is to
provide an access to affordable and safe medications to
consumers without diminishing revenues available for
pharmaceutical R&D. Although few solutions are suggested
in the literature, an in-depth analysis and effectiveness of
these solutions is required to solve the prescription drug
problem. Until then, drug reimportation will continue to be
a conundrum for US policymakers.
Conclusions
From its inception, the two main objections against
reimporting prescription drugs from across the border have
been the safety and authenticity of these drugs that could
jeopardize public health, and that the profits of drug
companies which is used for R&D of new drugs would be
seriously hurt. Views on reimportation are extremely
polarized among supporters and opponents with each trying
to justify their own interests. The legislative and
administrative bodies do not take the responsibility of the
reimported drugs. On the other hand, various consumer
groups and organizations continue to support the drug
reimportation. The motive for consumers is the direct cost-
savings offered by purchasing drugs from across the border.
Increasing support from consumers might push legislatives
to closely ponder over the issue of legality of drug
reimportation practices.
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